BMJ  2008;336:1460-1461 (28 June), doi:10.1136/bmj.a502

News

Drug maker’s PR firm is force behind blood clot awareness campaign

Ray Moynihan

1 Melbourne

The first 150 words of the full text of this article appear below.

The international public relations firm Fleishman-Hillard, working with funds from the drug maker Sanofi-Aventis, is helping run a high profile campaign to raise public awareness about blood clots.

The campaign, currently running in Australia under the banner of a coalition of health professionals, has generated headlines claiming that blood clots are more deadly than AIDS and articles suggesting that injections for patients at risk of developing clots may become mandatory.

A national expert on drugs, Alasdair Millar, said that any suggestion that all medical in-patients should receive injections to prevent clots are "extreme and scandalous" and "could cause more harm than good."

Evidence suggests that many hospital patients, whether surgical or medical, could benefit from a greater use of drugs to prevent serious clots, including low molecular weight heparins. But Professor Millar is concerned that these drugs will be given to patients who do not need them, thus exposing them . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Rapid Responses:

Read all Rapid Responses

DVT prophylaxis will prevent 5000 Australians from dieing of PE. Really?
David R Cole
bmj.com, 24 Jul 2008 [Full text]
Thromboprophylaxis in medical inpatients and DoH guidance
Shoaib Faruqi, et al.
bmj.com, 2 Mar 2009 [Full text]
Access jobs at BMJ Careers
Whats new online at Student BMJ